MLN4924: A Selective NAE Inhibitor Illuminates Neddylation in mTORC1-Driven Tumorigenesis

Introduction

The ubiquitin-proteasome system and its regulatory modifications have emerged as pivotal in cellular homeostasis, cell cycle control, and cancer biology. Among these, the neddylation pathway—a post-translational modification involving conjugation of the ubiquitin-like protein NEDD8 to target substrates—regulates the activity, stability, and localization of a diverse set of proteins, most notably cullin-RING ligases (CRLs). Dysregulation of neddylation is increasingly linked to tumorigenesis, making the pathway a compelling target for anti-cancer therapeutic development. MLN4924 (SKU: B1036), a highly selective NEDD8-activating enzyme (NAE) inhibitor, has become an essential molecular tool for dissecting neddylation-dependent mechanisms, particularly in solid tumor models.

The Neddylation Pathway: From CRLs to Non-Cullin Substrates

Neddylation proceeds via a three-enzyme cascade: NEDD8-activating enzyme (E1/NAE), NEDD8-conjugating enzymes (E2s: UBE2M/UBC12 and UBE2F), and NEDD8-E3 ligases. This pathway was long thought to primarily regulate CRLs, which orchestrate the ubiquitination and proteasomal degradation of key cell cycle and signaling proteins. However, recent research has illuminated a broader substrate scope, implicating non-cullin proteins such as RHEB in oncogenic signaling (Zhang et al., The EMBO Journal, 2025).

In cancer, hyperactive neddylation—especially via the UBE2F-SAG axis—drives CRL5 and other substrate modifications, facilitating unchecked proliferation and survival. The link between neddylation and the mTORC1 pathway, a central regulator of anabolic metabolism and tumor growth, is particularly salient for hepatocellular carcinoma and other solid malignancies.

MLN4924: Mechanism of Action and Selectivity

MLN4924 is a small-molecule inhibitor targeting the NEDD8-activating enzyme with an IC₅₀ of 4 nM. Structurally, MLN4924 competitively binds to the nucleotide-binding site of NAE, thereby blocking NEDD8 activation and transfer to E2 conjugating enzymes. This results in the accumulation of un-neddylated cullins, abrogation of CRL activity, and impaired ubiquitination of downstream substrates.

Notably, MLN4924 exhibits pronounced selectivity over related enzymes—UAE, SAE, UBA6, and ATG7—with substantially higher IC₅₀ values for these off-targets. This selectivity is critical for dissecting neddylation-specific cellular phenotypes with minimal interference from other ubiquitin-like pathways. In cell-based assays, such as with HCT-116 colorectal carcinoma cells, MLN4924 induces dose-dependent inhibition of neddylation, leading to stabilization of substrates like CDT1 and triggering cell cycle arrest and apoptosis.

Interrogating mTORC1-Driven Tumorigenesis: New Insights from Neddylation Inhibition

While previous studies primarily addressed MLN4924’s impact on CRL-mediated protein turnover, emerging evidence highlights its utility in probing the intersection of neddylation and mTORC1 signaling. The recent work by Zhang et al. (The EMBO Journal, 2025) revealed that the small GTPase RHEB—a direct activator of mTORC1—is a neddylation substrate of the UBE2F-SAG axis. Neddylation at RHEB K169 enhances lysosomal localization and GTP-binding, potentiating mTORC1 activity and exacerbating liver tumorigenesis.

Genetic ablation of UBE2F in liver models led to mTORC1 inactivation, cell cycle blockade, and increased autophagy, collectively suppressing tumor growth. These findings position the neddylation pathway as a critical modulator of non-cullin substrates in cancer. MLN4924, by inhibiting NAE and broadly suppressing neddylation, thus offers a unique means to dissect both CRL-dependent and -independent oncogenic processes.

Applications of MLN4924 in Solid Tumor Models and Xenografts

In preclinical models, MLN4924 demonstrates robust tumor growth inhibition in various xenograft systems, including HCT-116 colorectal, H522, and Calu-6 lung carcinoma lines. Subcutaneous administration at 30–60 mg/kg significantly impedes tumor progression with minimal toxicity and negligible weight loss, supporting its utility in solid tumor models for translational research.

Beyond CRL substrates like CDT1, the ability of MLN4924 to suppress RHEB neddylation and mTORC1 activity opens new avenues for targeting metabolic and proliferative circuits in cancer. This is particularly relevant for hepatocellular carcinoma, where mTORC1 hyperactivation is observed in up to 50% of cases and correlates with poor patient prognosis (Zhang et al., 2025).

Technical Considerations for Experimental Use

MLN4924 is supplied as a solid compound (molecular weight: 443.53) with excellent solubility in DMSO (≥22.18 mg/mL) and ethanol (≥42.2 mg/mL), but is insoluble in water. For optimal activity, solutions should be prepared fresh and stored at -20°C, with short-term use recommended.

Researchers should consider appropriate controls for off-target ubiquitin-like modifications, given MLN4924’s selectivity, and validate pathway blockade via immunoblotting for neddylated cullins or RHEB. Integration into both in vitro and in vivo protocols enables mechanistic studies of cell cycle regulation, apoptosis, and autophagy, as well as anti-cancer efficacy in xenograft models.

Implications for Anti-Cancer Therapeutic Development

The demonstrated ability of MLN4924 to inhibit both CRL and non-cullin neddylation substrates underscores its value in cancer biology research. By targeting the NEDD8-activating enzyme, MLN4924 blocks multiple oncogenic pathways—spanning cell cycle regulators and metabolic effectors such as mTORC1. This multi-faceted mechanism supports its continued investigation as both a research reagent and a prototype for next-generation neddylation inhibitors.

Moreover, elucidation of the UBE2F-SAG axis and RHEB as neddylation substrates provides specific rationale for targeting the neddylation machinery in tumors dependent on mTORC1 signaling, particularly in liver cancer and potentially other solid malignancies. The convergence of CRL and mTORC1 pathway regulation through neddylation inhibition positions MLN4924 as a foundational tool for both mechanistic interrogation and preclinical therapeutic assessment.

Contrasting with Previous Literature: Novel Interpretations and Guidance

While earlier works such as "MLN4924: Advancing NEDD8-Activating Enzyme Inhibition in ..." provide comprehensive overviews of MLN4924’s pharmacological properties and applications in CRL regulation, this article extends the discussion to the emerging interface between neddylation and mTORC1 pathway modulation in tumorigenesis. By integrating recent findings on RHEB neddylation and the UBE2F-SAG axis, we highlight previously underappreciated mechanisms by which MLN4924 can disrupt both canonical and non-canonical neddylation targets. This expanded perspective aims to guide researchers in leveraging MLN4924 for studies of metabolic signaling, anti-cancer strategy development, and the exploration of new therapeutic targets within the neddylation landscape.

Conclusion

MLN4924 remains a cornerstone reagent for neddylation pathway inhibition in cancer research, with its selectivity and potency enabling fine dissection of CRL and non-cullin substrate regulation. The intersection of neddylation with the mTORC1 axis, as demonstrated by RHEB modification, underscores the pathway’s complexity and its relevance for anti-cancer therapeutic development. As research advances, MLN4924 will continue to illuminate novel regulatory nodes and inform the design of targeted interventions for solid tumor models and beyond.